Review Of Hysingla ER (hydrocodone extended release)) Dosing, Cost, Side Effects, Prescribing Information, And Abuse Deterrence | Priya Ravindranath, PharmD | RxEconsult
Menus

All Health Articles

Hysingla ER (Hydrocodone bitartrate) Cost, Side Effects, Dosage, Prescribing Information, and Abuse Deterrence Category: Pain Management by - December 1, 2014 | Views: 68131 | Likes: 1 | Comment: 1  

Hysingla ER

Brand Name: Hysingla ER
Generic Name: Hydrocodone bitartrate extended-release tablets

Medication Class: Opioid agonist
Similar DrugsZohydro ER (hydrocodone bitartrate)
Manufacturer: Purdue Pharma
FDA Approval Date: November 20, 2014
Launch Date: Early 2015

How does Hysingla ER work?

Hysingla ER (extended release) is a strong, long-acting narcotic pain reliever similar to oxycodone, fentanyl, and morphine. It binds to opioid receptors located in the central nervous system (CNS) including the brain and spinal cord. When these receptors are activated hey produce an analgesic (pain-relieving) effect. Unlike other opioid medications available on the market, the effects of Hysingla ER can last an entire day and is ideal for treating long-term severe pain.

Hysingla ER comes in a tablet that dissolves over time to allow slow release of hydrocodone into the bloodstream and less frequent dosing.

What is Hysingla ER’s indication for treatment?

Hysingla ER is an oral medication used for the management of severe pain that requires around the clock dosing.

How safe and effective is Hysingla ER?

A study was conducted in 905 patients to test the efficacy of Hysingla ER compared to a placebo. During a dose titration period of 45 days, all patients were dosed once daily with the medication (20 to 120 mg). 588 patients reached acceptable pain reduction and tolerability and continued on to the 12-week study comparing Hysingla ER to placebo. At the end of the trial, 10% of patients discontinued therapy (5% of Hysingla patients and 15% of placebo patients). Additionally, 5% of subjects discontinued due to adverse effects (6% of Hysingla patients and 3% of placebo patients). Patients had, at least, a 30% improvement in pain intensity using Hysingla ER when compared to placebo.

Interesting facts about Hysingla ER

  • Hysingla ER is a schedule II medication. It is the first oral extended-release hydrocodone formulation to last 24 hours.
  • This medication contains hydrocodone without acetaminophen (Tylenol) unlike many other pain medications on the market. Usage of this agent reduces the likelihood of patients suffering from acetaminophen-induced liver damage.
  • One Hysingla tablet taken once daily is equivalent to taking Vicodin tablets 4 to 6 times daily to receive the same total daily amount of hydrocodone.
  • It is the first and only hydrocodone product to have abuse-deterrent characteristics when chewed, snorted or injected. When crushed, broken or dissolved, it forms a thick gel and cannot be easily injected.
  • This medication is currently a part of the ER/LA Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). This requires the availability of educational programs for  safe prescribing and patient counseling information to health care professionals.

Next: Side Effects, Dosing, Drug Interactions 

 
 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2019 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap